- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- July 2024
- 148 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- July 2021
- 155 Pages
Global
From €2503EUR$2,750USD£2,146GBP
€5006EUR$5,500USD£4,291GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- February 2024
- 140 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Report
- April 2023
- 72 Pages
Global
From €3500EUR$4,120USD£3,106GBP
The Cervical Cancer Vaccine market is a subset of the larger Cervical Cancer Drugs market. Cervical Cancer Vaccines are designed to prevent the development of cervical cancer by targeting the Human Papillomavirus (HPV), which is the primary cause of the disease. Vaccines are typically administered to young women before they become sexually active, and are often recommended for women up to the age of 26. Vaccines are also recommended for men and women who are at high risk of developing cervical cancer.
The Cervical Cancer Vaccine market is highly competitive, with a number of companies offering products. These include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, and Pfizer. Other companies, such as CSL Limited, are also involved in the development of new vaccines. Show Less Read more
